The persistence of antibodies to glycoprotein X (gpX) in the serum of pigs experimentally infected with pseudorabies virus (PRV) was determined using an anti-gpX enzyme-linked immunosorbent assay (ELISA). Antibodies to gpX were detected for at least 365 days postchallenge in nonvaccinated pigs. Previous sensitization of pigs by vaccination with S/PRV had no apparent effect on the antibody response of pigs to gpX postchallenge. In determining previous exposure of pigs to PRV strains containing the gpX gene, the anti-gpX ELISA was highly specific, but its sensitivity was lower than the standard serological procedures currently used for detecting PRV antibodies.
The move toward a national pseudorabies eradication program has dictated a need for improved diagnostic tests. Of particular importance has been the need for a diagnostic serology test that would differentiate vaccinated pigs from infected pigs. Vaccination of pigs with pseudorabies virus (PRV) vaccines is commonly practiced. Vaccination will reduce mortalities, shorten growth arrest periods, and decrease the shedding of virulent PRV after challenge. l However, vaccination will not prevent infection or the establishment of latent infection with virulent virus. 7 Therefore, PRV exposure following vaccination needs to be assessed, but standard serological procedures are of limited value USDA-licensed gpX-deleted vaccines are available, S/PRV" and T/PRV. b Both vaccine strains also have the gene coding for thymidine kinase (TK) deleted from their genomes. The deletion of the TK gene reduces vaccine virulence and the likelihood of the establishment of latent infection with the vaccine strain. 8 The WPRV vaccine has an accompanying USDAlicensed diagnostic test, the anti-gpX enzyme-linked immunosorbent assay (ELISA), c which is specific for antibodies to gpX in pig serum. 3 This test ignores antibody titers in animals vaccinated with WPRV but detects antibodies in animals infected with field strains or vaccinated with strains that contain the gpX gene. because they cannot distinguish antibodies induced by
The objectives of this study were to determine the natural infection from those induced by PRV vaccines. persistence of antibodies to gpX in nonvaccinated and Considerable effort has been directed at this problem S/PRV-vaccinated pigs following PRV infection and because the inability to differentiate these antibody to compare the anti-gpX ELISA with the standard seresponses markedly decreases the efficiency of eradi-rological procedures used to assess PRV exposure. cation programs utilizing vaccination. 11 The creation of gene-deleted vaccines and their associated diagnostic tests are major breakthroughs in overcoming the Materials and methods problem with conventional vaccines and standard se-Tria1 I rological procedures.
Four 8-wk-old pigs from a PRV-negative herd were chal-Genetically engineered PRV vaccines have deletions lenged intranasally with 10 5.0 plaque forming units (PFU) of of nonessential genes. One example is the deletion of the Shope strain of PRV. Sera were harvested from blood the gene coding for glycoprotein X (gpX), which is collected on the day of challenge and 48 times over the next secreted by PRV-infected cells. Glycoprotein X is a 365 days. major antigen interacting with an infected pig's im-Trial II mune system. 4 However, antibodies to gpX have no PRV neutralizing activity so the deletion of the gpX blood collected from all pigs on the day of vaccination, days 14, 62, and 66 PV, the day of challenge, and days 3, 7, 10, 14, 21, and 28 postchallenge (PC). To determine the persis-during a second incubation. If no gpX antibodies are present tence of antibodies to PRV, Group B was also bled on days in the test sera, the conjugated gpX antibodies are free to 42, 53, 67, and 115 PC. react with the gpX antigen. Conversely, if gpX antibodies are present in the test serum, the enzyme-conjugated monoclonal antibodies are blocked from reacting with the antigen.
Test sera
Following this incubation period, the unreacted conjugate is A total of 1,372 pig sera were assayed. These were divided into 6 groups. Included in these groups were the pig sera utilized in Trials I and II. Group 1. Sera from 1,017 nonvaccinated pigs originating from PRV-negative herds (no clinical or serological evidence of PRV infection). Group 2. Sera from 157 pigs vaccinated with 1 or 2 doses of S/PRV and bled 3 wk PV. Group 3. Sera from 35 pigs vaccinated with 1 or 2 doses of T/PRV and bled 3 wk PV. Group 4. Sera from 60 pigs vaccinated with killed or modified live gpX-positive PRV vaccines and bled 3 wk PV. Group 5. Sera from 48 pigs infected intranasally with PRV strain VDL 4892 and bled 2-4 wk PC. Group 6. Sera with varying virus neutralizing antibody titers from 55 nonvaccinated pigs from PRV-infected herds.
Assays
Sera were tested with the anti-gpX ELISA, the anti-PRV ELISA, d the serum virus neutralization (SVN) test, and by radioimmunoprecipitation (RIP). 6 The anti-gpX ELISA is a competitive enzyme immunoassay, utilizing monoclonal antibodies that are specific for gpX. The manufacturer describes the principles of the test in the kit insert 3 as follows. The anti-gpX ELISA is performed in a PRV antigen-coated microwell using a 2-fold (1:2) serum dilution. During the first incubation, PRV antibodies present in the serum, including those produced against gpX, react with antigens on the plastic. Subsequent to a wash step, an anti-gpX monoclonal antibody conjugate is added to the microwell and is allowed to compete for the gpX viral antigen removed by washing and a substrate/chromagen solution is added. In the presence of enzyme, the substrate is converted to a product that reacts with the chromophore to generate a blue color. The absorbance at 650 nm, A(650), is measured by a spectrophotometer. Results are calculated by dividing the A(650) of the sample by the mean A(650) of the negative control, resulting in an S/N value. The quantity of antibodies to gpX is inversely proportional to the A(650) and, thus, to the S/N value. If S/N is less than or equal to 0.70, the test is classified as positive for antibodies to the gpX antigen of PRV. If S/N is greater than 0.70, the test is classified negative. The presence of PRV antibodies, including anti-gpX, indicates a previous exposure to a field strain of PRV or application of conventionally modified live-or killed-virus vaccines. The presence of PRV antibodies detected by the anti-PRV ELISA and/or SVN test but absence of antibodies to gpX antigen as assessed by the anti-gpX ELISA indicates a response to a gpX-deleted vaccine.
The anti-PRV ELISA is a commercially available indirect enzyme immunoassay used as a screening test for PRV antibodies. 9 The presence or absence of antibody is determined by calculating the ratio of the sample absorbance to the weak positive absorbance (S/P). Serum samples with S/P ratios of less than 0.40 are classified negative for PRV antibodies. If the S/P ratio is greater than or equal to 0.40, the sample is classified positive for PRV antibodies.
Serum virus neutralization titers were determined as described. 2 The SVN test is the standard serological test used to detect antibody to PRV.
Radioimmunoprecipitation using (35S) methionine-labelled subunit diagnostic antigen (SUDA) combined with selected sera was performed as described. 6 
Results

Trial I
Prior to challenge, the 4 pigs were serologically negative by anti-PRV ELISA and anti-gpX ELISA. After challenge, the pigs developed positive reactions to both tests. Group anti-gpX ELISA values were positive by day 8 PC and peaked at day 300 PC (Fig. 1 ). Anti-PRV ELISA values were above the positive threshold by day 8 PC and peaked at day 280 PC (Fig. 2) . Considerable variation in antibody response was seen among individual pigs, even though they were from the same litter. However, all pigs remained positive for both tests from day 8 to day 365 PC.
Trial II
All 15 pigs were serologically negative for PRV antibodies at the commencement of the trial. Anti-PRV ELISA values for pigs in Groups B and C were positive 14 days PV and remained positive throughout the trial. Anti-gpX ELISA values remained negative PV and prechallenge. The group mean anti-PRV ELISA and anti-gpX ELISA values from day 0 to day 28 PC are shown in Table 1 . All control pigs were anti-PRV ELISA and anti-gpX ELISA positive from day 10 to day 28 PC. The mean anti-gpX ELISA values for Group B are shown in Fig. 1 . The anti-gpX ELISA values for all vaccinates were positive by day 21; however, the mean value for the anti-gpX ELISA was positive by day 14 for all vaccinates. The 5 pigs in Group B that were maintained for 115 days remained positive by the anti-gpX ELISA. Anti-PRV ELISA values for vaccinates increased PC and peaked at day 28 PC. The mean values for Group B are shown in Fig. 2 . There was little variation in anti-PRV ELISA or anti-gpX ELISA reactivity in nonvaccinated pigs. However, vaccinated pigs with similar anti-PRV ELISA reactivity had considerable variation in anti-gpX ELISA reactivity PC.
Evaluation of serological tests
The distribution of anti-PRV ELISA and anti-gpX ELISA results in the 6 groups is shown in Table 2 . Pigs in Group 1 (nonvaccinated, noninfected) were classi- fied as negative by both assays with a high degree of accuracy. Antibodies to gpX were detected in none of the S/PRV vaccinated pigs and one of the T/PRV vaccinated pigs 3 wk PV, whereas all of these gpX-deleted vaccinated pigs tested were positive by the anti-PRV ELISA. The anti-gpX ELISA was less sensitive than the anti-PRV ELISA at detecting pigs exposed to gpXpositive strains of PRV either by vaccination, experimental intranasal inoculation, or by natural infection. Twenty-five of 141 pigs positive by anti-PRV ELISA were negative by anti-gpX ELISA. These 25 pigs had anti-PRV ELISA S/P ratios ranging from 0.84 to 3.22. Fifteen of the pigs had SVN titers less than 2, and the other 10 pigs had titers of either 1:2 or 1:4.
The overall distributions of anti-gpX ELISA reac-Figs. 3 and 4, respectively. The S/N values of nonvaccinated pigs (mean = SD = 0.12) were significantly 3 < 0.05) higher than those of S/PRV-vaccinated pigs (mean = SD = 0.10). However, the means of both groups were well above the positive threshold, and there was little deviation from mean reactivity in either group.
Radioimmunoprecipitation was performed on pooled serum samples of pigs in Groups 1, 2, and 3 and on the serum sample in Group 3 reacting on the anti-gpX ELISA. The SUDA did not react with antibodies in any of the sera tested but did react with antibodies in control serum from PRV-infected pigs. The monoclonal antibody to gpX used in the anti-gpX ELISA also reacted with SUDA, suggesting SUDA is the same tivity for Group 1 and Groups 2 and 5 are shown in as gpX. 
Discussion
Using an S/N ratio of 0.70 as the positive/negative threshold, the anti-gpX ELISA is highly specific for evaluating the exposure of pigs to PRV strains containing the gpX antigen. All pigs vaccinated with S/PRV and 34 of 35 pigs vaccinated with T/PRV were negative on this test. The 1 pig vaccinated with T/PRV that was positive by anti-gpX ELISA was negative by RIP. This suggests the gpX antibodies were not present in the serum of this pig and that the positive reaction on the anti-gpX ELISA was due to nonspecific competition with the conjugated monoclonal antibody to gpX. The lower S/N values for S/PRV-vaccinated pigs as compared with nonvaccinated pigs does not appear to be due to the production of gpX antibodies by S/PRV vaccinates. A second vaccination with S/PRV did not induce an anamnestic response detectable by the anti-gpX ELISA, and pooled sera from S/PRV-vaccinated pigs were negative by RIP. It is likely that the binding of other PRV antibodies to the PRV antigen-coated microwell caused slight steric hindrance to the binding of the conjugated anti-gpX monoclonal antibody. Regardless, S/PRV sera showed relatively little deviation from mean reactivity and were well separated from the S/N ratios found among sera from pigs tested 2-4 weeks after PRV challenge. As all field strains of PRV contain the gpX antigen, 10 the anti-gpX ELISA can effectively distinguish between naturally infected and vaccinated pigs if a gpX-deleted vaccine has been used. However, currently the anti-gpX ELISA can officially only be used to differentiate animals vaccinated with S/PRV because the license for a diagnostic test is restricted to use with its companion vaccine.
The ELISA discrimination endpoint chosen to distinguish positive and negative sera requires a compromise between an assay's sensitivity and specificity. The high specificity of the anti-gpX ELISA was associated with some loss of sensitivity as compared to the anti-PRV ELISA. This lower sensitivity means the anti-gpX ELISA would be less effective than the anti-PRV ELISA as a screening test for detection of antibody to PRV in pig sera. However, when used as a monitoring test subsequent to using a gpX-deleted vaccine, the anti-gpX ELISA is superior to the anti-PRV ELISA, which is of limited value in assessing PRV infection following vaccination because it cannot distinguish between naturally infected and vaccinated pigs.
For the anti-gpX ELISA to be an effective assay, it needs to detect PRV antibodies in PRV-exposed pigs, both nonvaccinated and vaccinated, for extended periods. This study demonstrated that positive levels of gpX antibody are detectable for at least 365 days and 115 days PC in nonvaccinated and S/PRV-vaccinated pigs, respectively. The sensitization of vaccinates with a live PRV gpX-deleted vaccine did not significantly alter a pig's humoral immune response to gpX when exposed to wild type PRV. Antibodies to gpX were detectable earlier PC in nonvaccinates, probably as a result of greater viral replication in these pigs. However, by 21 days PC all vaccinates were positive by anti-gpX ELISA, and the level of antibody response was similar between groups. In Trial II, the greater variation in anti-gpX ELISA reactivity in vaccinated pigs as compared with control pigs is unexplained. However, it is important that all vaccinates remained anti-gpX ELISA positive PC.
Pigs from Trial I were not assayed to determine if any were latently infected with PRV. However, the peaks and troughs in anti-gpX ELISA reactivity over time and the fact that the greatest group mean reactivity of both assays did not occur until 9 months PC is suggestive of latent infection with recrudescence.
Sources and manufacturers
a. PRV/Marker ®, SyntroVet Inc., Lenexa, KS. b. Tolvid®, The Upjohn Co., Kalamazoo, MI. c. HerdChek®: Anti-PRV-gpX, IDEXX Corp., Portland, ME. d. HerdChek®: Anti-PRV (S), IDEXX Corp., Portland, ME.
